- Home
- Life Sciences
- Pharmaceutical
- Pharmaceutical Analysis & Statistics, May 2013
Talk to Alison
00 1 718 618 48 97
Search inside this page
Top countries
- United States (2 756)
- World (2 354)
- Japan (701)
- China (236)
- Germany (637)
-
- France (628)
- India (205)
- Europe (685)
- Italy (599)
- Spain (595)
- United Kingdom (594)
- Canada (168)
- Australia (150)
- South Korea (76)
- Switzerland (56)
- Israel (74)
- Netherlands (44)
- Sweden (36)
- Ireland (24)
- Denmark (29)
Publication dates
Publishers
- All
- Global Data
All regions
-
- Bahrain (1)
- Bangladesh (4)
- China (236)
- Georgia (4)
- India (205)
- Indonesia (15)
- Israel (74)
- Japan (701)
- Jordan (1)
- Kazakhstan (1)
- Kuwait (1)
- Malaysia (6)
- Oman (1)
- Philippines (9)
- Qatar (1)
- Saudi Arabia (12)
- Singapore (24)
- South Korea (76)
- Sri Lanka (2)
- Taiwan (18)
- Thailand (2)
- Turkey (6)
- United Arab Emirates (5)
- Uzbekistan (1)
- Yemen (2)
-
- Austria (12)
- Belarus (1)
- Belgium (21)
- Bosnia and Herzegovina (1)
- Bulgaria (2)
- Croatia (1)
- Cyprus (1)
- Czech Republic (12)
- Denmark (29)
- Estonia (3)
- Finland (10)
- France (628)
- Germany (637)
- Greece (6)
- Hungary (5)
- Iceland (1)
- Ireland (24)
- Italy (599)
- Latvia (4)
- Liechtenstein (1)
- Lithuania (4)
- Luxembourg (2)
- Malta (1)
- Netherlands (44)
- Norway (16)
- Poland (9)
- Portugal (5)
- Romania (4)
- Russian Federation (27)
- San Marino (1)
- Serbia and Montenegro (2)
- Slovakia (slovak Republic) (4)
- Slovenia (1)
- Spain (595)
- Sweden (36)
- Switzerland (56)
- Ukraine (3)
- United Kingdom (594)
-
- Australia (150)
- Austria (12)
- Belgium (21)
- Canada (168)
- Chile (2)
- Czech Republic (12)
- Denmark (29)
- Estonia (3)
- Finland (10)
- France (628)
- Germany (637)
- Greece (6)
- Hungary (5)
- Iceland (1)
- Ireland (24)
- Israel (74)
- Italy (599)
- Japan (701)
- Luxembourg (2)
- Mexico (21)
- Netherlands (44)
- New Zealand (13)
- Norway (16)
- Poland (9)
- Portugal (5)
- Slovenia (1)
- South Korea (76)
- Spain (595)
- Sweden (36)
- Switzerland (56)
- Turkey (6)
- United Kingdom (594)
- United States (2 756)
data types
Free Market Research Guides to Download
Pharmaceutical Analysis & Statistics, May 2013
You might be interested in: therapeutics, cancer, drug, more »
» Purchase Premium Reports
1-30 of about 6 500 reports
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Europe, United Kingdom
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : France, World, Spain, Italy, Germany, Japan, India, China, Europe, United States, United Kingdom
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
Actonel (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Actonel (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Actonel (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
Evista (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : United States, World, Spain, Italy, France, Germany, Japan, India, China, Europe, United Kingdom
Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Viviant/Combriza (Osteoporosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Spain, Italy, Japan, United States, World
Aprela (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Aprela (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Aprela (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : United States, World, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
Romosozumab (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Romosozumab (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Romosozumab (Osteoporosis) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom
Ostora (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Ostora (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Ostora (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, United States, Japan, China
Recalbon/Bonoteo (Osteoporosis) - Forecast and Market Analysis to 2022
- $ 6 995
- Industry report
- February 2013
- by Global Data
Recalbon/Bonoteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Recalbon/Bonoteo (Osteoporosis) - Forecast and Market ...
- Industries : Pathology
- Countries : Japan, United States, World
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017
- $ 5 995
- Industry report
- April 2013
- by Global Data
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017 Summary Idiopathic Pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia ...
- Industries : Therapy
OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
- $ 5 995
- Industry report
- April 2013
- by Global Data
OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017 Summary Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, ...
- Industries : Pathology
- Countries : United States
PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022 Summary Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory ...
- Industries : Drug and Medication
- Countries : United States
PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) ...
- Industries : Pathology
- Countries : United States
PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - France ...
- Industries : Pathology
- Countries : France
PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - ...
- Industries : Pathology
- Countries : Germany
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) ...
- Industries : Pathology
- Countries : United Kingdom
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan ...
- Industries : Pathology
- Countries : Japan
PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy ...
- Industries : Pathology
- Countries : Italy
PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- April 2013
- by Global Data
PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain ...
- Industries : Pathology
- Countries : Spain
PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis ...
- Industries : Pathology
- Countries : United Kingdom
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and ...
- Industries : Pathology
- Countries : Germany
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - France Drug Forecast and ...
- Industries : Pathology
- Countries : France
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market ...
- Industries : Pathology
- Countries : United States
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market ...
- Industries : Pathology
- Countries : India
PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market ...
- Industries : Pathology
- Countries : China
PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and ...
- Industries : Pathology
- Countries : Canada
» Download Public Reports
About 30 000 reports
Export (harmonized System): Pharmaceutical Products
- Industry data
- April 2013
Monthly, From 1992 To 2013
Source: U.S. Department of Labor: Bureau of Labor Statistics
U.s. Vitamin D Sector Analysis
May 2013Vaccine Market In Tanzania
May 2013The Swazi Pharmaceutical Industry
May 2013U.s. Pharmaceutical Industry
May 2013» Read our Company Profiles
About 200 CompaniesGlaxoSmithKline P.L.C.
United StatesNovartis Inc.
SwitzerlandJohnson and Johnson
United StatesPfizer Inc.
United StatesGlaxoSmithKline PLC
United KingdomReportlinker.com © Copyright 2013. All rights reserved.
